

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	1	NMR and "N15-Bcl-XL"	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/08/16 09:46
L2	1	"N15-Bcl-XL"	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/08/16 09:46
L3	85	"TCTP"	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/08/16 09:46
L4	7	"TCTP" and Bcl-2	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/08/16 09:46
L5	7	"TCTP" and Bcl-2	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/08/16 09:46
L6	1	"TCTP" and Bcl-2 and "13C labeling"	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/08/16 09:46
L7	7	"TCTP" and Bcl-2 and protein	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/08/16 09:46
L8	159	Bcl-XL and Bcl-2 and NMR	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/08/16 10:06
L9	740	"Bcl-XL" or "Bcl-2" same NMR	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/08/16 09:47
L10	740	"Bcl-XL" or "Bcl-2" same NMR	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/08/16 09:47
L11	45	bcl-2 and BH3 same antibody	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/08/16 09:47
L12	16	Bcl-XL and Bcl-2 and NMR and 530/350.ccls.	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/08/16 09:48

L13	2	Bcl-XL and Bcl-2 and NMR and 530/327.ccls.	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/08/16 09:48
L14	2	Bcl-XL and Bcl-2 and NMR and 530/326.ccls.	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/08/16 09:48
L15	1	Bcl-XL and Bcl-2 and NMR and 514/617.ccls.	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/08/16 09:48
L16	9	Bcl-XL and Bcl-2 and NMR and 514/12.ccls.	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/08/16 09:48
L17	10	Bcl-XL and Bcl-2 and NMR and 435/7.1.ccls.	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/08/16 09:48
L18	3	Bcl-XL and Bcl-2 and NMR and 530/388.8.ccls.	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/08/16 10:06
S1	1	NMR and "N15-Bcl-XL"	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2004/11/05 15:20
S2	1	"N15-Bcl-XL"	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2004/11/05 15:30
S3	76	"TCTP"	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2004/11/05 15:31
S4	4502	"TCTP" or TR3	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2004/11/05 15:31
S5	7	"TCTP" and Bcl-2	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2004/11/05 15:31
S6	4	"TCTP" and Bcl-2 and measuring	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2004/11/05 16:03

S7	1	"TCTP" and Bcl-2 and "13C labeling"	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2004/11/05 16:03
S8	1	"TCTP" and Bcl-2 and "13C"	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2004/11/05 16:03
S9	7	"TCTP" and Bcl-2 and protein	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2004/11/08 12:01
S10	117	Bcl-XL and Bcl-2 and NMR	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2005/08/16 09:47
S11	117	"Bcl-XL" and "Bcl-2" and NMR	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2004/11/08 12:01
S12	11	"Bcl-XL" and "Bcl-2" same NMR	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2004/11/08 13:12
S13	581	"Bcl-XL" or "Bcl-2" same NMR	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2004/11/08 13:13
S14	25	"Bcl-2" same NMR	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2004/11/09 10:29
S15	37	bcl-2 and BH3 same antibody	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2004/11/09 10:30
S16	5	"190965".pn.	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2004/11/10 10:56

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1653rbm

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 28	PATDPAFULL - New display fields provide for legal status data from INPADOC
NEWS	4	FEB 28	BABS - Current-awareness alerts (SDIs) available
NEWS	5	MAR 02	GBFULL: New full-text patent database on STN
NEWS	6	MAR 03	REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS	7	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	8	MAR 22	KOREAPAT now updated monthly; patent information enhanced
NEWS	9	MAR 22	Original IDE display format returns to REGISTRY/ZREGISTRY
NEWS	10	MAR 22	PATDPASPC - New patent database available
NEWS	11	MAR 22	REGISTRY/ZREGISTRY enhanced with experimental property tags
NEWS	12	APR 04	EPFULL enhanced with additional patent information and new fields
NEWS	13	APR 04	EMBASE - Database reloaded and enhanced
NEWS	14	APR 18	New CAS Information Use Policies available online
NEWS	15	APR 25	Patent searching, including current-awareness alerts (SDIs), based on application date in CA/CAPLUS and USPATFULL/USPAT2 may be affected by a change in filing date for U.S. applications.
NEWS	16	APR 28	Improved searching of U.S. Patent Classifications for U.S. patent records in CA/CAPLUS
NEWS	17	MAY 23	GBFULL enhanced with patent drawing images
NEWS	18	MAY 23	REGISTRY has been enhanced with source information from CHEMCATS
NEWS	19	JUN 06	The Analysis Edition of STN Express with Discover! (Version 8.0 for Windows) now available
NEWS	20	JUN 13	RUSSIAPAT: New full-text patent database on STN
NEWS	21	JUN 13	FRFULL enhanced with patent drawing images
NEWS	22	JUN 27	MARPAT displays enhanced with expanded G-group definitions and text labels
NEWS	23	JUL 01	MEDICONF removed from STN
NEWS	24	JUL 07	STN Patent Forums to be held in July 2005
NEWS	25	JUL 13	SCISEARCH reloaded
NEWS	26	JUL 20	Powerful new interactive analysis and visualization software, STN AnaVist, now available
NEWS	27	AUG 11	Derwent World Patents Index(R) web-based training during August
NEWS	28	AUG 11	STN AnaVist workshops to be held in North America
NEWS EXPRESS			JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN

NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:15:21 ON 16 AUG 2005

=> INDEX bioscience

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 10:15:45 ON 16 AUG 2005

74 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view search error messages that display as 0* with SET DETAIL OFF.

=> Bcl-XL and Bcl-2 and NMR

- 18 FILE BIOSIS
- 3 FILE BIOTECHABS
- 3 FILE BIOTECHDS
- 2 FILE BIOTECHNO
- 8 FILE CANCERLIT
- 21 FILE CAPLUS

22 FILES SEARCHED...

- 2 FILE DDFU
- 1 FILE DISSABS
- 3 FILE DRUGU
- 7 FILE EMBASE
- 2 FILE ESBIODASE

34 FILES SEARCHED...

- 7 FILE IFIPAT
- 3 FILE JICST-EPLUS
- 3 FILE LIFESCI
- 12 FILE MEDLINE
- 1 FILE NTIS
- 1 FILE PASCAL

54 FILES SEARCHED...

- 8 FILE SCISEARCH
- 10 FILE TOXCENTER
- 135 FILE USPATFULL
- 20 FILE USPAT2

71 FILES SEARCHED...

- 2 FILE WPIDS

73 FILES SEARCHED...

- 2 FILE WPINDEX

23 FILES HAVE ONE OR MORE ANSWERS, 74 FILES SEARCHED IN STNINDEX

L1 QUE BCL-XL AND BCL-2 AND NMR

=> d rank

F1	135	USPATFULL
F2	21	CAPLUS
F3	20	USPAT2
F4	18	BIOSIS
F5	12	MEDLINE
F6	10	TOXCENTER
F7	8	CANCERLIT
F8	8	SCISEARCH
F9	7	EMBASE
F10	7	IFIPAT
F11	3	BIOTECHABS
F12	3	BIOTECHDS
F13	3	DRUGU
F14	3	JICST-EPLUS
F15	3	LIFESCI
F16	2	BIOTECHNO
F17	2	DDFU
F18	2	ESBIOBASE
F19	2	WPIDS
F20	2	WPINDEX
F21	1	DISSABS
F22	1	NTIS
F23	1	PASCAL

=> file caplus medline biosis toxcenter cancerlit
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.36	2.57

FILE 'CAPLUS' ENTERED AT 10:17:58 ON 16 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 10:17:58 ON 16 AUG 2005

FILE 'BIOSIS' ENTERED AT 10:17:58 ON 16 AUG 2005
Copyright (c) 2005 The Thomson Corporation

FILE 'TOXCENTER' ENTERED AT 10:17:58 ON 16 AUG 2005
COPYRIGHT (C) 2005 ACS

FILE 'CANCERLIT' ENTERED AT 10:17:58 ON 16 AUG 2005

=> Bcl-XL and Bcl-2 and NMR
L2 69 BCL-XL AND BCL-2 AND NMR

=> dup remove
ENTER L# LIST OR (END):L2
PROCESSING COMPLETED FOR L2
L3 31 DUP REMOVE L2 (38 DUPLICATES REMOVED)

=> d ti 1-20

L3 ANSWER 1 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN
TI Methods and compounds useful to induce apoptosis in cancer cells

L3 ANSWER 2 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 1
TI An inhibitor of Bcl-2 family proteins induces
regression of solid tumours

L3 ANSWER 3 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN
 TI Conversion of apoptotic proteins

L3 ANSWER 4 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN
 TI Solution structure of Bcl-w determined by NMR spectrometry and its use for screening and design of interacting compounds

L3 ANSWER 5 OF 31 MEDLINE on STN
 TI Characterization of protein-ligand interactions by high-resolution solid-state NMR spectroscopy.

L3 ANSWER 6 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN
 TI Solution Conformations of Wild-Type and Mutated Bak BH3 Peptides via Dynamical Conformational Sampling and Implication to Their Binding to Antiapoptotic Bcl-2 Proteins

L3 ANSWER 7 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 2
 TI Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-XL

L3 ANSWER 8 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 3
 TI Small-molecule inhibitors of Bcl-2 protein

L3 ANSWER 9 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 4
 TI Structural studies of apoptosis and ion transport regulatory proteins in membranes

L3 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 5
 TI Defining the p53 DNA-binding domain/Bcl-xL-binding interface using NMR

L3 ANSWER 11 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 6
 TI Solution Structure of Human BCL-w: Modulation of Ligand Binding by the C-Terminal Helix

L3 ANSWER 12 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 7
 TI Cancer Prevention by Tea Polyphenols Is Linked to Their Direct Inhibition of Antiapoptotic Bcl-2-Family Proteins

L3 ANSWER 13 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 8
 TI Discovery, Characterization, and Structure-Activity Relationships Studies of Proapoptotic Polyphenols Targeting B-Cell Lymphocyte/Leukemia-2 Proteins

L3 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 9
 TI Solution Structure of the BHRF1 Protein From Epstein-Barr Virus, a Homolog of Human Bcl-2

L3 ANSWER 15 OF 31 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
 TI Novel chemically-stabilized helices of the BCL-2 family induce apoptosis of leukemia cells.

L3 ANSWER 16 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 10
 TI A Novel Approach for Characterizing Protein Ligand Complexes: Molecular Basis for Specificity of Small-Molecule Bcl-2 Inhibitors

L3 ANSWER 17 OF 31 MEDLINE on STN DUPLICATE 11
 TI Enhanced resistance to salt, cold and wound stresses by overproduction of animal cell death suppressors Bcl-xL and Ced-9 in tobacco cells - their possible contribution through improved function of organella.

L3 ANSWER 18 OF 31 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN

TI A view to a kill: Ligands for Bcl-2 family proteins.

L3 ANSWER 19 OF 31 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN

TI Identification of small molecular inhibitors of BH3 and Bcl-xL interaction.

L3 ANSWER 20 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 12

TI Discovery of Small-Molecule Inhibitors of Bcl-2 through Structure-Based Computer Screening

=> d ti 21-38

L3 ANSWER 21 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 13

TI Solution structure of the antiapoptotic protein bcl-2

L3 ANSWER 22 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 14

TI Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-XL

L3 ANSWER 23 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 15

TI NMR Studies of the Anti-Apoptotic Protein Bcl-xL in Micelles

L3 ANSWER 24 OF 31 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN

TI Privileged molecules for protein binding identified from NMR-based screening.

L3 ANSWER 25 OF 31 MEDLINE on STN DUPLICATE 16

TI Rationale for Bcl-xL/Bad peptide complex formation from structure, mutagenesis, and biophysical studies.

L3 ANSWER 26 OF 31 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN

TI Targeting the mitochondrial redox state of leukemia and lymphoma cells with PK11195 for effective therapy.

L3 ANSWER 27 OF 31 MEDLINE on STN DUPLICATE 17

TI An approach for high-throughput structure determination of proteins by NMR spectroscopy.

L3 ANSWER 28 OF 31 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN

TI Assessing pore formation by BCL-2 during apoptosis in cell lines and human leukemic cells: Cysteine 158 in the alpha 5 helical loop is in an aqueous environment.

L3 ANSWER 29 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 18

TI Refolding, Purification, and Characterization of a Loop Deletion Mutant of Human Bcl-2 from Bacterial Inclusion Bodies

L3 ANSWER 30 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 19

TI Recombinant mouse Bcl-2(1-203). Two domains connected by a long protease-sensitive linker

L3 ANSWER 31 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 20

TI X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death

=> d ab bib 2, 7, 8, 10, 18, 23, 31

L3 ANSWER 2 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 1

AB Proteins in the Bcl-2 family are central regulators of programmed cell death, and members that inhibit apoptosis, such as Bcl-XL and Bcl-2, are overexpressed in many cancers and contribute to tumor initiation, progression and resistance to therapy. Bcl-XL expression correlates with chemo-resistance of tumor cell lines, and redns. in Bcl-2 increase sensitivity to anticancer drugs and enhance in vivo survival. The development of inhibitors of these proteins as potential anticancer therapeutics has been previously explored, but obtaining potent small-mol. inhibitors has proved difficult owing to the necessity of targeting a protein-protein interaction. Here, using NMR-based screening, parallel synthesis and structure-based design, the authors have discovered ABT-737, a small-mol. inhibitor of the antiapoptotic proteins Bcl-2, Bcl-XL and Bcl-w, with an affinity two to three orders of magnitude more potent than previously reported compds. Mechanistic studies reveal that ABT-737 does not directly initiate the apoptotic process, but enhances the effects of death signals, displaying synergistic cytotoxicity with chemotherapeutics and radiation. ABT-737 exhibits single-agent-mechanism-based killing of cells from lymphoma and small-cell lung carcinoma lines, as well as primary patient-derived cells, and in animal models, ABT-737 improves survival, causes regression of established tumors, and produces cures in a high percentage of the mice.

AN 2005:467373 CAPLUS

TI An inhibitor of Bcl-2 family proteins induces regression of solid tumours

AU Oltersdorf, Tilman; Elmore, Steven W.; Shoemaker, Alexander R.; Armstrong, Robert C.; Augeri, David J.; Belli, Barbara A.; Bruncko, Milan; Deckwerth, Thomas L.; Dinges, Jurgen; Hajduk, Philip J.; Joseph, Mary K.; Kitada, Shinichi; Korsmeyer, Stanley J.; Kunzer, Aaron R.; Letai, Anthony; Li, Chi; Mitten, Michael J.; Nettesheim, David G.; Ng, Shi Chung; Nimmer, Paul M.; O'Connor, Jacqueline M.; Oleksijew, Anatol; Petros, Andrew M.; Reed, John C.; Shen, Wang; Tahir, Stephen K.; Thompson, Craig B.; Tomaselli, Kevin J.; Wang, Baole; Wendt, Michael D.; Zhang, Haichao; Fesik, Stephen W.; Rosenberg, Saul H.

CS Idun Pharmaceuticals, San Diego, CA, 92121, USA

SO Nature (London, United Kingdom) (2005), 435(7042), 677-681

CODEN: NATUAS; ISSN: 0028-0836

PB Nature Publishing Group

DT Journal

LA English

RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 2

AB Antiapoptotic Bcl-2-family proteins Bcl-2 and Bcl-XL have been recently validated as drug discovery targets for cancer. Here, by using a combination of mol. modeling, NMR-based structural anal., fluorescence polarization assays, and cell-based assays, we have designed and characterized a novel proapoptotic compound targeting these proteins. Our compound, Apogossypol, is capable of binding and inhibiting Bcl-2 and Bcl-XL with high affinity and induces apoptosis of tumor cell lines. Mechanistic studies on the action of our compound were also performed via confocal microscopy that provided real-time detection of the interaction with Bcl-XL in intact cells. Finally, preliminary data on cells freshly isolated from patients affected by chronic lymphocytic leukemia strongly suggest potential applications of Bcl-2 antagonists as chemosensitizers in cancer therapy.

AN 2004:261470 CAPLUS

DN 141:133679

TI Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-XL
AU Becattini, Barbara; Kitada, Shinichi; Leone, Marilisa; Monosov, Edward; Chandler, Sharon; Zhai, Dayong; Kipps, Thomas J.; Reed, John C.; Pellecchia, Maurizio
CS The Burnham Institute, La Jolla, CA, 92037, USA
SO Chemistry & Biology (2004), 11(3), 389-395
CODEN: CBOLE2; ISSN: 1074-5521
PB Cell Press
DT Journal
LA English
RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 3
AB A review. Approaches to drug discovery are varied and range from high-resolution NMR solution structure of targeted mols. to rational design. This review is focused on the use of small-mol. inhibitors of Bcl-2 as therapeutic agents. Members of the Bcl-2 family of proteins are crucial regulators of apoptotic cell death. Human cancers have been found to over-express Bcl-2 and Bcl-XL. Cells with high levels of these antiapoptotic mols. are usually resistant to a wide spectrum of chemotherapeutic drugs. Targeting the Bcl-2 family of proteins with small-mol. inhibitors has therefore become an attractive potential therapy for a variety of cancers. The role of Bcl-2 in sabotaging the success of cytotoxic agents suggests that novel treatments should be devised to target Bcl-2-over-expressing tumor cells and induce apoptosis directly. In this article, we will provide a review of potential small-mol. inhibitors as anticancer agents. The de-regulated over-expression of Bcl-2 and Bcl-XL is directly related to cancer cell survival and resistance to chemotherapeutic drugs, making antagonists or inhibitors of these proteins very promising candidates for use in cancer therapy.

AN 2004:545110 CAPLUS
DN 142:16057
TI Small-molecule inhibitors of Bcl-2 protein
AU Pulley, Heather; Mohammad, Ramzi
CS Division of Hematology and Oncology, Department of Internal Medicine/Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, 48201, USA
SO Drugs of the Future (2004), 29(4), 369-381
CODEN: DRFUD4; ISSN: 0377-8282
PB Prous Science
DT Journal; General Review
LA English

L3 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 5
AB P53 exerts its tumor suppressor activity through both transcription-dependent and transcription-independent processes. Although the transcription-dependent activity of p53 has been extensively studied, the mechanism for transcription-independent p53-mediated tumor suppression is less well known. Recently, it was reported that p53 can directly induce mitochondrial permeabilization and promote apoptosis. This occurs through complexation of the DNA-binding region of p53 with the anti-apoptotic proteins Bcl-xL and Bcl-2 (Mihara, M. et al. (2003) Mol. Cell 11, 577-590). Using NMR spectroscopy we show that the interaction surface on p53 involves the same region that is used by the protein to contact DNA. The p53-binding site on Bcl-xL consists of the carboxy-terminus of the first α -helix, the loop between α 3 and α 4, and the loop between α 5 and α 6 of Bcl-xL. Furthermore, the interaction of p53 with Bcl-xL is blocked by the

binding of a 25-residue peptide derived from the BH3 region of the pro-apoptotic protein referred to as Bad.

AN 2004:114202 CAPLUS
DN 140:266453
TI Defining the p53 DNA-binding domain/Bcl-xL-binding interface using NMR
AU Petros, Andrew M.; Gunasekera, Angelo; Xu, Nan; Olejniczak, Edward T.; Fesik, Stephen W.
CS Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL, 60064, USA
SO FEBS Letters (2004), 559(1-3), 171-174
CODEN: FEBLAL; ISSN: 0014-5793
PB Elsevier Science B.V.
DT Journal
LA English
RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 18 OF 31 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 2002:500148 BIOSIS
DN PREV200200500148
TI A view to a kill: Ligands for Bcl-2 family proteins.
AU Rutledge, Stacey E. [Reprint author]; Chin, Jason W.; Schepartz, Alanna [Reprint author]
CS Department of Chemistry, Yale University, PO Box 208107, New Haven, CT, 06520-8107, USA
SO Current Opinion in Chemical Biology, (August, 2002) Vol. 6, No. 4, pp. 479-485. print.
ISSN: 1367-5931.
DT Article
General Review; (Literature Review)
LA English
ED Entered STN: 25 Sep 2002
Last Updated on STN: 25 Sep 2002

L3 ANSWER 23 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 15
AB The Bcl-2 family of proteins play a pivotal role in the regulation of programmed cell death. One of the postulated mechanisms for the function of these proteins involves the formation of ion channels in membranes. As a first step to structurally characterize these proteins in a membrane environment, we investigated the structure of a Bcl-xL mutant protein when incorporated into small detergent micelles. This form of Bcl-xL lacks the loop (residues 49-88) between helix 1 and helix 2 and the putative C-terminal transmembrane helix (residues 214-237). Below the critical micelle concentration (CMC), Bcl-xL binds detergents in the hydrophobic groove that binds to pro-apoptotic proteins. However, above the CMC, Bcl-xL undergoes a dramatic conformational change. Using NMR methods, we characterized the secondary structure of Bcl-xL in the micelle-bound form. Like Bcl-xL in aqueous solution, the structure of the protein when dissolved in dodecylphosphocholine (DPC) micelles consists of several α -helices separated by loops. However, the length and position of the individual helices of Bcl-xL in micelles differ from those in aqueous solution. The location of Bcl-xL within the micelle was examined from the anal. of protein-detergent NOEs and limited proteolysis. In addition, the mobility of the micelle-bound form of Bcl-xL was investigated from NMR relaxation measurements. On the basis of these studies, a model is proposed for the structure, dynamics, and location of Bcl-xL in micelles. In this model, Bcl-xL has a loosely packed, dynamic structure in micelles, with helices 1 and 6 and possibly helix 5 partially buried in

the hydrophobic interior of the micelle. Other parts of the protein are located near the surface or on the outside of the micelle.

AN 2000:567804 CAPLUS
DN 133:292518
TI NMR Studies of the Anti-Apoptotic Protein Bcl-xL in Micelles
AU Losonczi, Judit A.; Olejniczak, Edward T.; Betz, Stephen F.; Harlan, John E.; Mack, Jamey; Fesik, Stephen W.
CS Pharmaceutical Discovery Division, Abbott Laboratories, Abbott Park, IL, 60064, USA
SO Biochemistry (2000), 39(36), 11024-11033
CODEN: BICHAW; ISSN: 0006-2960
PB American Chemical Society
DT Journal
LA English
RE.CNT 62 THERE ARE 62 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 31 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 20
AB The Bcl-2 family of proteins regulate programmed cell death by an unknown mechanism. Here we describe the crystal and solution structures of a Bcl-2 family member, Bcl-xL. The structures consist of two central, primarily hydrophobic α -helices, which are surrounded by amphipathic helices. A 60-residue loop connecting helices $\alpha 1$ and $\alpha 2$ was found to be flexible and non-essential for anti-apoptotic activity. The three functionally important Bcl-2 homol. regions (BH1, BH2 and BH3) are in close spatial proximity and form an elongated hydrophobic cleft that may represent the binding site for other Bcl-2 family members. The arrangement of the α -helices in Bcl-xL is reminiscent of the membrane translocation domain of bacterial toxins, in particular diphtheria toxin and the colicins. The structural similarity may provide a clue to the mechanism of action of the Bcl-2 family of proteins.

AN 1996:317544 CAPLUS
DN 125:3874
TI X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death
AU Muchmore, Steven W.; Sattler, Michael; Liang, Heng; Meadows, Robert P.; Harlan, John E.; Yoon, Ho; Nettlesheim, David; Chang, Brian S.; Thompson, Craig B.; et al.
CS NMR Research, Abbott Laboratories, Abbott Park, IL, 60064, USA
SO Nature (London) (1996), 381(6580), 335-341
CODEN: NATUAS; ISSN: 0028-0836
PB Macmillan Magazines
DT Journal
LA English